Corporate Action

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration partner, the Japanese pharmaceutical company Solasia Pharma K.K. (“Solasia”), has confirmed its continued strong commitment in the development of arfolitixorin. Solasia will contribute with its expertise and participate in defining the detailed design of the […]

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin Read More »

Isofol presents a clinical development plan for arfolitixorin

GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today presents the company’s continued strategy and clinical development program for the drug candidate arfolitixorin. The board and management, together with external experts, have evaluated the available data for arfolitixorin and decided to conduct a clinical phase I/II study to document

Isofol presents a clinical development plan for arfolitixorin Read More »

Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting

GOTHENBURG, Sweden, December 13, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that all of the company’s board members will leave their respective positions if Jan-Eric Österlund is elected as a new member of the board at the extraordinary general meeting that has been convened on a request from a group of

Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting Read More »

Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm

GOTHENBURG, Sweden, October 18, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the “Company”), announced today that the prospectus prepared by the Company in connection with the listing on Nasdaq Stockholm has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen). The prospectus contains updated financial

Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm Read More »

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option

GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”) fully guaranteed new share issue with preferential rights for the Company’s existing shareholders (the “Rights Issue”), which ended on June 10, 2021, was oversubscribed. Due to the strong demand from strategic investors, a directed

Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option Read More »

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million

GOTHENBURG, Sweden, May 25, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the “Company”) Board of Directors resolved on May 18, 2021, on an issue of shares of a maximum of 62,524,474 shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). If the Rights Issue

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million Read More »

Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million

GOTHENBURG, Sweden, May 18, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the ”Company”) Board of Directors has today, pursuant to the authorization granted by the extraordinary general meeting held on May 14, 2021 (“the EGM”), resolved on an issue of shares of a maximum of 62,524,474 shares

Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million Read More »

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million

GOTHENBURG, Sweden, April 28, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), hereby announces that the Board of Directors has the intention to carry out an issue of shares of approximately SEK 400 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”). An extraordinary general meeting will

Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million Read More »

Isofol’s rights issue oversubscribed

GOTHENBURG, Sweden, June 3, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”) fully guaranteed new share issue with preferential rights for the Company’s existing shareholders (the “Rights Issue”), which ended on June 1, 2020, was oversubscribed. Due to the strong demand from strategic investors, a directed

Isofol’s rights issue oversubscribed Read More »

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million

GOTHENBURG, Sweden, May 14, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”) Board of Directors resolved on May 7, 2020, on a fully guaranteed new share issue of a maximum of 42,739,736 shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). Through the

Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million Read More »

Scroll to Top